Creathor Venture and HTGF invest in Sirion Biotech

The capital will be used to further promote the firm's technologies and services and approach further clients in the EU and US-market through internationalisation. Additionally, the firm is planning to further support the development of new vector-technologies.

The investor was attracted to the positive current market situation and the results of internal research activities of the company which according to Creator Ventures proves significant market demand.

Company
Martinsried-based Sirion Biotech is a producer of genetically modified cells and technology provider in the area of viral vector systems. Founded in 2006, the company's core competence is the development and marketing of adenoviral and lentiviral vector technologies in the field of target validation.

People
Karlheinz Schmelig is partner at Creathor Venture and Marco Winzer managed the deal for High-Tech Gründerfonds.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Expansion
• Healthcare
• Now researching
• Germany